Table 5.

LCM output parameters

	Class 1		Class 2
Class Proportions	0.61		0.39
Utility parameters	Parameter	T-Ratio	Parameter	T-ratio
Generic parameters
Subcutaneous - high frequency (Reference category: oral)	−0.899*	−3.380	− 0.802*	−4.800
Subcutaneous - low frequency (Reference category: oral)	−0.899*	−3.380	0	0
Intravenous - high frequency (Reference category: oral)	−0.940*	−3.470	− 0.753*	− 4.380
Intravenous - low frequency (Reference category: oral)	− 0.940*	− 3.470	− 0.514*	− 3.110
Out of pocket cost	− 0.012*	−2.400	−0.017*	− 4.140
Overall survival	1.226*	8.670	0.291*	9.440
Short remission period (Reference category – long remission period)	−1.059*	−5.860	−0.750*	−5.440
Mild side effects	−0.009*	−2.230	−0.009*	− 2.890
No severe side effects (Reference category – some severe side effects)	1.251*	3.930	0.644*	3.960
Neither treatment constant	−2.294*	−3.390	−0.710*	− 3.020
Interaction effect parameters
Out of pocket costs (Carers) (Reference category – out of pocket costs – people living with MM)	0	0	0	0
Out of pocket costs (Physicians) (Reference category – out of pocket costs – people living with MM)	0	0	−0.033*	−2.240
Out of pocket costs (Nurses) (Reference category – out of pocket costs – people living with MM)	0	0	−0.064*	−3.780
Overall survival (Carers)	0	0	0.108*	2.490
Overall survival (Physicians)	0	0	0.449*	4.120
Overall survival (Nurses)	−0.468*	−2.970	0.439*	4.250
Short remission period (Carers) (Reference category – long remission period – people living with MM)	−1.366*	−2.770	0	0

*p < .05, Restricted log likelihood: − 2405.961, Log likelihood: − 1022.241, Rho-squared: 0.452, Number of respondents: 219, Number of choice observations: 2190